BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22008893)

  • 1. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
    Kawamura Y; Arase Y; Ikeda K; Seko Y; Imai N; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ohmoto Y; Amakawa K; Tsuji H; Kumada H
    Am J Gastroenterol; 2012 Feb; 107(2):253-61. PubMed ID: 22008893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis.
    Cheung KS; Seto WK; Fung J; Mak LY; Lai CL; Yuen MF
    World J Gastroenterol; 2017 Nov; 23(44):7863-7874. PubMed ID: 29209127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
    Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
    Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma.
    Maegawa FB; Shehorn L; Aziz H; Kettelle J; Jie T; Riall TS
    JAMA Netw Open; 2019 Jan; 2(1):e187142. PubMed ID: 30657533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.
    Kawamura Y; Arase Y; Ikeda K; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Inao M; Mochida S; Kumada H
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):597-605. PubMed ID: 26707683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    Ioannou GN; Green P; Kerr KF; Berry K
    J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
    Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
    S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
    Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
    Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.
    Yatsuji S; Hashimoto E; Tobari M; Taniai M; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2009 Feb; 24(2):248-54. PubMed ID: 19032450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Pinyopornpanish K; Al-Yaman W; Butler RS; Carey W; McCullough A; Romero-Marrero C
    Am J Gastroenterol; 2021 Nov; 116(11):2258-2269. PubMed ID: 34212895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.